RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.37
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$34.81

22 Oct
2026

-0.080

OPEN

$34.83

-0.23%

HIGH

$34.89

1,540,735

LOW

$34.69

TARGET
$39.125 12.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 174.3 xxx
DPS (cps) 38.6 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 20.6 xxx
Dividend Yield 1.1% xxx
Div Pay Ratio(%) 22.2% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.52%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.95

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 19/08 - (franking ex-div 6.55c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx154.5
DPS All xxxxxxxxxxxxxxx35.2
Sales/Revenue xxxxxxxxxxxxxxx8,343.1 M
Book Value Per Share xxxxxxxxxxxxxxx659.0
Net Operating Cash Flow xxxxxxxxxxxxxxx2,664.9 M
Net Profit Margin xxxxxxxxxxxxxxx26.94 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx24.16 %
Return on Invested Capital xxxxxxxxxxxxxxx21.80 %
Return on Assets xxxxxxxxxxxxxxx17.69 %
Return on Equity xxxxxxxxxxxxxxx24.16 %
Return on Total Capital xxxxxxxxxxxxxxx26.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,918.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx417 M
Long Term Debt xxxxxxxxxxxxxxx775 M
Total Debt xxxxxxxxxxxxxxx1,192 M
Goodwill - Gross xxxxxxxxxxxxxxx4,200 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,126 M
Price To Book Value xxxxxxxxxxxxxxx4.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx261.5 M
Capex % of Sales xxxxxxxxxxxxxxx3.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,316 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2,189 M
Research & Development xxxxxxxxxxxxxxx558 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

05/10/2026

1

Buy

$36.20

3.99%

Ord Minnett has updated its healthcare sector forecasts for stocks under coverage after revising currency assumptions, resulting in EPS reductions of -0%-3% across its coverage.

Preferred sector picks remain Buy-rated ResMed and CSL (Accumulate). ResMed is favoured for strong sleep growth, margin recovery and more than US$1.85bn of FY27 capital returns.

CSL is supported by expected 7% annual immunoglobulin revenue growth through FY29, improving Behring margins, cost discipline and buybacks, despite a -US$50m FY27 currency headwind.

The $36.20 target and Buy rating are maintained for ResMed.

This is a summary of research released by Ord Minnett last Friday.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

12/08/2026

2

Overweight

$39.90

14.62%

Jarden maintains an Overweight rating for ResMed with its target price decreased to $39.90 from $40.20 following the release of fourth-quarter financial results.

Non-GAAP net profit after tax reached US$428m, beating market expectations by 1.8% despite a -2.6% EBIT shortfall caused by gross margin compression and higher research and development expenses.

The analyst notes robust underlying momentum, highlighted by 8% growth in United States sleep devices surpassing prior expectations.

To counter persistent inflationary pressures carrying into FY27, management plans to implement modest product price increases alongside further supply-chain initiatives.

The broker's estimates reflect near-term earnings per share cuts of -1%-2% while maintaining an optimistic outlook on core business strength.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Rudi’s View: Quality At Home, Value Abroad

Oct 22 2026 - Rudi's View
2
Rudi’s View: Lower Bond Yields & Other Catalysts

Oct 21 2026 - Rudi's View
3
Rudi’s View: Stocks To Own & Best To Avoid

Oct 15 2026 - Rudi's View
4
Rudi’s View: Bravura, Capricorn Metals, Downer EDI, PLS, Symal & More

Oct 08 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 30, 2026

Sep 30 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
2
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
3
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
4
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
5
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
6
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
7
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
8
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
9
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
10
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps